专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20020146685A1 Immunoassays for anti-HCV antibodies 有权
标题翻译：免疫测定抗HCV抗体
公开(公告)号：US20020146685A1
公开(公告)日：2002-10-10
申请号：US09881654
申请日：2001-06-14
发明人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
IPC分类号： C12Q001/70 , G01N033/53 , G01N033/537 , G01N033/543 , A61K039/29 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74
CPC分类号： C07K14/005 , C07K2319/00 , C12N2770/24222 , G01N33/5767 , G01N2333/18 , G01N2469/10 , G01N2469/20
摘要： HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.
摘要翻译：提供包含NS3 / 4a构象表位和多表位融合抗原的HCV免疫测定，以及用于免疫测定的免疫测定固体支持物。

42. 发明申请

US20020141974A1 Hepatitis therapeutics 审中-公开
标题翻译：肝炎治疗
公开(公告)号：US20020141974A1
公开(公告)日：2002-10-03
申请号：US09912679
申请日：2001-07-24
发明人： Douglas J. Jolly , Stephen M.W. Chang , William T.L. Lee , Kay Townsend , Joanne O'Dea
IPC分类号： A61K048/00 , A61K039/29
CPC分类号： C07K14/005 , A61K39/00 , C07K14/52 , C07K14/535 , C07K14/55 , C12N2730/10122 , C12N2770/24222 , Y02A50/466
摘要： The present invention provides methods of treating hepatitis C infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of a hepatitis C antigen, such that an immune response is generated. Also provided are vector constructs which direct the expression of at least one portion of a hepatitis C antigen, as well as recombinant viruses which carry such vector constructs.
摘要翻译：本发明提供了治疗丙型肝炎感染的方法，包括施用引导丙型肝炎抗原的至少一种免疫原性部分的表达的载体构建体的步骤，使得产生免疫应答。还提供了引导丙型肝炎抗原的至少一部分的表达的载体构建体，以及携带这种载体构建体的重组病毒。

43. 发明申请

US20020136740A1 Vaccines containing ribavirin and methods of use thereof 失效
标题翻译：含有利巴韦林的疫苗及其使用方法
公开(公告)号：US20020136740A1
公开(公告)日：2002-09-26
申请号：US09929955
申请日：2001-08-15
发明人： Matti Sallberg , Catharina Hultgren
IPC分类号： A61K048/00 , A61K039/12 , A61K031/7056 , C12Q001/70 , A61K031/70 , A01N043/04 , C12P019/34 , A01N063/00 , A61K039/29
CPC分类号： A61K39/29 , A01K67/0271 , A61K31/7056 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/39 , A61K2039/53 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/57 , A61K2121/00 , A61K2123/00 , C07K14/005 , C07K16/109 , C12N7/00 , C12N2740/16134 , C12N2770/24022 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , G06F19/00 , G06Q50/22 , Y02A50/464 , Y02A90/22 , Y02A90/26
摘要： Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.
摘要翻译：公开了用于增强疫苗在家畜，运动或宠物物种和人类中的作用的组合物和方法。更具体地，公开了包含利巴韦林和抗原，优选具有存在于丙型肝炎病毒（HCV）中的表位的抗原的疫苗组合物用于治疗和预防疾病，优选HCV感染。

44. 发明申请

US20020123038A1 Oligonucleotide for highly sensitive detection of hepatitis C virus and method for detection thereof 失效
标题翻译：用于丙型肝炎病毒高度敏感检测的寡核苷酸及其检测方法
公开(公告)号：US20020123038A1
公开(公告)日：2002-09-05
申请号：US09984316
申请日：2001-10-29
发明人： Toshiki Taya , Takahiko Ishiguro , Juichi Saito
IPC分类号： C12Q001/70 , C07H021/04 , A61K031/70 , A01N043/04 , C12P019/34 , A61K039/29
CPC分类号： C12Q1/707 , C12Q2531/143
摘要： An oligonucleotide useful for specific amplification of HCV RNA, or highly sensitive detection and identification of HCV RNA, and a combination thereof. A detection method using RNA amplification step, wherein the oligonucleotide of SEQ ID NO: 11 is used as a first primer and the oligonucleotide of SEQ ID NO: 6 or 7 as a second primer, the oligonucleotide of SEQ ID NO: 12 is used as a first primer and the oligonucleotide of SEQ ID NO: 7 as a second primer, or the oligonucleotide of SEQ ID NO: 13 is used as a first primer and the oligonucleotide of SEQ ID NO: 9 as a second primer.
摘要翻译：可用于特异性扩增HCV RNA的寡核苷酸或HCV RNA高度灵敏的检测和鉴定及其组合。使用RNA扩增步骤的检测方法，其中将SEQ ID NO：11的寡核苷酸用作第一引物，将SEQ ID NO：6或7的寡核苷酸用作第二引物，将SEQ ID NO：12的寡核苷酸用作第一引物和作为第二引物的SEQ ID NO：7的寡核苷酸或SEQ ID NO：13的寡核苷酸用作第一引物，将SEQ ID NO：9的寡核苷酸用作第二引物。

45. 发明申请

US20020090607A1 Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins 有权
标题翻译：丙型肝炎病毒蛋白的抗原表位和镶嵌多肽
公开(公告)号：US20020090607A1
公开(公告)日：2002-07-11
申请号：US09758308
申请日：2001-01-10
发明人： Howard A. Fields , Yury E. Khudyakov
IPC分类号： C12Q001/70 , C07K014/01 , A61K039/29
CPC分类号： C07K14/005 , A61K2039/525 , C12N2770/24222
摘要： Antigenic epitopes of hepatitis C virus (HCV) and mosaic HCV polypeptides useful as reagents in assays for the diagnosis or monitoring of HCV in a biological sample. The antigenic epitopes and mosaic polypeptides are also useful for the construction of immunogenic pharmaceutical compositions, such as vaccines. The mosaic polypeptides are artificial composite proteins constructed from diagnostically relevant antigenic regions derived from different HCV proteins. Preferably, the mosaic polypeptides contain antigenic epitopes from the core protein, NS3 protein, and NS4 protein. The preferred mosaic polypeptides optionally contain an additional antigenic epitope from either the NS4 protein or the NS5a protein or both.
摘要翻译：用于诊断或监测生物样品中HCV的测定中的丙型肝炎病毒（HCV）和镶嵌HCV多肽的抗原表位可用作试剂。抗原表位和镶嵌多肽也可用于构建免疫原性药物组合物，如疫苗。镶嵌多肽是由衍生自不同HCV蛋白质的诊断相关抗原区构建的人造复合蛋白。优选地，镶嵌多肽含有来自核心蛋白，NS3蛋白和NS4蛋白的抗原表位。优选的马赛克多肽任选地含有来自NS4蛋白或NS5a蛋白的另外的抗原表位或两者。

46. 发明申请

US20020076415A1 Hepatitis C virus gene products 审中-公开
标题翻译：丙型肝炎病毒基因产物
公开(公告)号：US20020076415A1
公开(公告)日：2002-06-20
申请号：US09736959
申请日：2000-12-14
发明人： Jing-Hsiung Ou , Zhenming Xu
IPC分类号： A61K039/29 , C12Q001/70 , C07H021/04 , C07K014/01 , C07K016/08
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/53 , C07K16/109 , C12N2770/24222
摘要： The present invention provides heretofore unidentified proteins and smaller peptides of HCV, which are produced by translation of the HCV core RNA through a frameshifting mechanism. In one embodiment the invention provides a protein that is about 125 to about 161 amino acids long depending on the HCV genotypes. The smaller peptides of the invention range in length from about 13 amino acids to over 50 amino acids. The invention also includes DNA sequences that encode the polypeptides of the invention, antibodies directed against the polypeptides of the invention, and therapeutic compositions including vaccines and anti-viral compositions. Additionally, the invention provides for methods for diagnosing, preventing and treating hepatitis C using the compounds and compositions of the invention.
摘要翻译：本发明提供了迄今为止未知的蛋白质和较小的HCV肽，其通过通过移码机制翻译HCV核心RNA产生。在一个实施方案中，本发明提供了约125至约161个氨基酸长度的蛋白质，这取决于HCV基因型。本发明较小的肽的长度范围为约13个氨基酸至超过50个氨基酸。本发明还包括编码本发明多肽的DNA序列，针对本发明多肽的抗体，以及包括疫苗和抗病毒组合物的治疗组合物。此外，本发明提供了使用本发明的化合物和组合物诊断，预防和治疗丙型肝炎的方法。

47. 发明申请

US20020058044A1 Complex Of Lipo-Viro-Particles, Method Of Preparation And Applications 失效
标题翻译： Lipo-Viro-particle的复合物，制备方法和应用
公开(公告)号：US20020058044A1
公开(公告)日：2002-05-16
申请号：US09917915
申请日：2001-07-31
申请人： Bio Merieux
发明人： Patrice Andre , Vincent Lotteau , Glaucia Paranhos-Baccala , Florence Komurian-Pradel
IPC分类号： C12Q001/70 , G01N033/53 , G01N033/537 , G01N033/543 , A61K039/395 , A61K039/42 , A61K039/21 , A61K039/29 , C12N005/06 , C12N005/16
CPC分类号： C12N7/00 , A61K39/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/525 , C12N2770/24251
摘要： The complex consists of LVPs associated with human immunoglobulins having a density of less than 1.063 g/ml. It may be obtained by a method according to which a plasma or serum sample taken from a patient infected with HCV is made available, the LVPs are separated from the said sample by centrifugation according to their density, and the LVPs associated with human immunoglobulins are separated using protein A, anti-human immunoglobulins or any other molecule capable of binding human immunoglobulins.
摘要翻译：复合物由密度小于1.063g / ml的人免疫球蛋白相关的LVP组成。可以通过根据该方法获得从感染HCV的患者获取的血浆或血清样品，根据其密度通过离心将所述LVP与所述样品分离，并且分离与人免疫球蛋白相关的LVP 使用蛋白A，抗人免疫球蛋白或能够结合人免疫球蛋白的任何其他分子。

48. 发明申请

US20020037934A1 Method for treating hepatitis 有权
标题翻译：治疗肝炎的方法
公开(公告)号：US20020037934A1
公开(公告)日：2002-03-28
申请号：US09925970
申请日：2001-08-10
申请人： New York University School of Medicine
发明人： Ashok Amin , Steven Abramson
IPC分类号： A61K039/395 , C12Q001/70 , A61K039/40 , A61K039/42 , A61K039/29 , C12N005/06 , C12N005/16 , A01N025/00
CPC分类号： C07K16/241 , A61K2039/505 , C07K2317/24
摘要： Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).
摘要翻译：可以通过向有需要的患者施用有效量的中和分泌的TNFα的作用的化合物来治疗肝炎。两种类型的这些化合物是人p75 TNF受体的细胞外配体结合蛋白，如依那西普（Enbrel）和中和TNFα活性的人源化单克隆抗体，如英夫利昔单抗（Remicade）。

49. 发明申请

US20020028214A1 METHOD OF PRODUCING SPECIFIC IMMUNOGLOBIN TO BLOCK HCV INFECTION 失效
标题翻译：生产特异性免疫球蛋白以阻断HCV感染的方法
公开(公告)号：US20020028214A1
公开(公告)日：2002-03-07
申请号：US09117292
申请日：1998-08-26
发明人： MARCELLO PIAZZA
IPC分类号： A61K039/29 , A61K039/42
CPC分类号： C07K16/109 , A61K38/00
摘要： A drug which protects individuals against hepatitis C virus (HCV) is made of HCV hyperimmune globulins, which guarantee a substantial hyperimmunity against HCV thanks to a substantial hyperconcentration of virus C neutralizing antibodies. This hyperconcentration is obtained from blood of a large number of antiHCV positive blood donors. The material used for the preparation of the HCV hyperimmune globulins is made of up to 100 % of antiHCV positive blood units.
摘要翻译：保护个人免受丙型肝炎病毒（HCV）的药物由HCV超免疫球蛋白制成，其由于病毒C中和抗体的实质性高浓度而保证对HCV的实质性超免疫性。这种高浓度是从大量抗HCV阳性献血者的血液获得的。用于制备HCV超免疫球蛋白的材料由高达100％的抗-HHC阳性血液单位制成。

50. 发明申请

US20010046501A1 Superantigen enhancement of specific immune responses 审中-公开
标题翻译：超抗原增强特异性免疫反应
公开(公告)号：US20010046501A1
公开(公告)日：2001-11-29
申请号：US09808718
申请日：2001-03-15
发明人： Howard M. Johnson , Barbara A. Torres , Kominsky L. Scott
IPC分类号： A61K039/21 , A61K039/29 , A61K039/00
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/55544 , A61K2039/57
摘要： The invention relates to superantigen mediated expansion of antigen-specific T cells for cancer and infectious agent treatment/prophylaxis. Mice were injected with inactivated B16F10 mouse melanoma cells, followed by injection with a combined SEA/SEB injection or a sham injection on days 3 and 6, followed by day 4 challenge with live melanoma cells. The SEA/SEB recipient mice survived longer post-challenge and had a higher CTLs against tumor cells than did the sham injected mice. SEA/SEB TCR activation has been reported to be independent of antigen specificity of TCRs. This invention provides a method whereby a combination of Staphylococcal enterotoxin superantigens is used to enhance specific immune responses to activating antigens to enhance immune responses against cancers and infectious agents.
摘要翻译：本发明涉及抗原特异性T细胞用于癌症和感染剂治疗/预防的超抗原介导的扩增。向小鼠注射灭活的B16F10小鼠黑素瘤细胞，随后在第3天和第6天用SEA / SEB联合注射或假注射注射，随后用活黑素瘤细胞进行第4天的攻击。 SEA / SEB受体小鼠在攻击后存活时间更长，与假注射的小鼠相比，肿瘤细胞的CTLs更高。据报道SEA / SEB TCR活化与TCR的抗原特异性无关。本发明提供了一种方法，其中葡萄球菌肠毒素超抗原的组合用于增强对活化抗原的特异性免疫应答，以增强针对癌症和感染因子的免疫应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式